Skip to main content

Table 8 CSS analysis for all patients

From: The platelet to lymphocyte ratio is a potential inflammatory marker predicting the effects of adjuvant chemotherapy in patients with stage II colorectal cancer

Characteristics

 

RMSTb (95%CI)

HRc (95%CI)

P valuea

Interaction p

Non-chemotherapy

Chemotherapy

Total

–

53.8 (51.7–55.3)

56.2 (50.1–57.1)

0.673 (0.412–1.101)

0.112

–

Sex

Male

53.2 (50.7–55.3)

55.9 (54.4–57.1)

0.598 (0.330–1.084)

0.086

0.393

Female

54.5 (51.3–56.5)

56.8 (55.0–58.0)

0.882 (0.365–2.134)

0.781

 

Age (years)

≤55

54.3 (47.9–57.4)

56.3 (54.2–57.7)

0.669 (0.218–2.053)

0.479

0.986

56–60

55.4 (47.4–58.5)

56.8 (54.2–58.3)

0.656 (0.132–3.250)

0.602

 

61–65

53.3 (46.5–57.0)

55.7 (52.8–57.4)

0.720 (0.224–2.314)

0.519

 

66–70

53.2 (48.2–56.3)

57.3 (53.7–58.8)

0.172 (0.036–0.834)

0.013

 

> 70

53.6 (50.6–55.8)

54.6 (50.0–57.2)

1.240 (0.458–3.356)

0.671

 

Location

Rectum

52.2 (49.2–54.5)

55.6 (53.8–56.9)

0.586 (0.311–1.105)

0.094

0.445

Colon

55.2 (52.6–56.9)

56.9 (55.4–58.0)

0.775 (0.355–1.691)

0.521

 

Size (cm)

≤5.0

54.0 (51.3–55.9)

56.1 (54.6–57.2)

0.737 (0.389–1.396)

0.347

0.154

> 5.0

53.7 (50.4–55.8)

56.3 (54.4–57.5)

0.638 (0.289–1.408)

0.262

 

Differentiation

Well-moderate

53.9 (51.9–55.4)

56.3 (55.1–57.2)

0.685 (0.406–1.157)

0.154

0.548

Poor

52.0 (43.1–56.2)

54.7 (47.5–58.1)

0.625 (0.139–2.805)

0.535

 

T category

3

56.4 (54.1–58.0)

57.6 (55.4–58.7)

0.797 (0.307–2.069)

0.640

0.377

4

51.8 (48.7–54.0)

55.6 (54.2–56.7)

0.579 (0.326–1.030)

0.059

 

CEAd (ng/mL)

< 5

54.6 (51.9–56.6)

56.8 (55.3–57.8)

0.774 (0.376–1.596)

0.487

0.554

≥5

53.5 (50.2–55.7)

55.1 (52.6–56.8)

0.682 (0.300–1.549)

0.357

 

Examined lymph nodes

< 12

52.0 (47.8–54.9)

53.6 (50.4–55.7)

0.906 (0.407–2.018)

0.810

0.517

≥12

54.4 (52.2–56.1)

57.1 (55.9–57.9)

0.590 (0.316–1.102)

0.094

 

PLRe

≤130

56.0 (53.7–57.6)

56.0 (54.4–57.1)

1.016 (0.494–2.087)

0.967

0.116

> 130

51.3 (48.2–53.8)

56.5 (54.9–57.8)

0.440 (0.217–0.893)

0.019

 
  1. a P value of the log-rank test
  2. b RMST: the restricted mean survival time
  3. c HR: Hazard Ratio, chemotherapy patients vs. non-chemotherapy patients
  4. d CEA: carcinoembryonic antigen
  5. e PLR: platelet to lymphocyte ratio